- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01465256
Postpolypectomy Bleeding in Patients With Antiplatelet Therapy
Postpolypectomy Bleeding in Patients Undergoing Colonoscopy on Antiplatelet Therapy. - Multicenter, Prospective Observational Study -
Study Overview
Status
Intervention / Treatment
Detailed Description
Based on very limited evidences, ASGE recommended that endoscopic procedures may be performed on patients taking aspirin. However in a survey of ASGE members regarding their endoscopic practice, 81% would consider discontinuation of aspirin before colonoscopy and 66% would not perform snare polypectomy if patients had not discontinued aspirin. Although a large prospective randomized control trial would be the ideal way to address this issue theoretically, the investigators hypothesized that there are no differences of the post polypectomy bleeding rate in patients whether continuous taking aspirin prior to polypectomy or not.
In this study, we classified the patients into two groups; the patients who can stop taking aspirin before colon polypectomy will be enrolled into group 1, and the patients who take both thienopyridines and aspirin for their underlying disease and should keep take aspirin during colon polypectomy will be enrolled into group 2. The patients of group 1 stop taking aspirin 7 days before polypectomy.
thromboembolism. Exclusions are as follow; patients taking anti-thrombotic agents, patients have low a platelet count (<80,000/mm3) and/or prolongated PT/aPTT, patients who have chronic renal disease (creatinine>3mg/dl over 6 months), patients who have GI malignancies, patients who are over ASA classification class III, over 2 score of HAS-BLED and over 1 of CHAD2 score. The expected enrolled patients number is 500 patients (250 in each group).
All cases of polypectomy are performed with identical methodology; resection after epinephrine mixture injection under blended or mixed current wave. The data includes the patients information such as sex, age, body weight, BMI and vascular disease history such as hypertension, diabetes, ischemic heart disease, cerebrovascular disease, COPD, modified HAS-BLED score and CHADS2 score. The data of polyp related factor include number of polyps, bleeding status(acute, early, delayed/minimal, moderate, sever), endoscopist (staff or fellow), bowel preparation status, polyp character (shape, location, pathology) and procedures for bleeding (clipping, APC, epinephrine injection, band ligation etc.).
All procedure will be performed with the endoscopist blinded to the patient status of whether the patient is taking aspirin continuously or not.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 140-743
- Recruiting
- Soonchunhyang univerisity hospital
-
Contact:
- Hyun Gun Kim, MD., PhD.
- Email: medgun@schmc.ac.kr
-
Principal Investigator:
- Hyun Gun Kim, MD., PhD.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patients who take low dose aspirin (75~160mg) for primary prevention of vascular disease and low risk for thromboembolism.
Exclusion Criteria:
- The patients who taking anti-thrombotic agents,
- The patients who taking thienopyridines or other NSAID with aspirin,
- The patients who have low platelet count(<80,000/mm3) and prolongated PT/aPTT in laboratory test,
- The patients who have chronic renal disease (creatinine>3mg/dl over 6 months),
- The patients who have polyps over than 1 cm in size or thick pedicle over 1 cm,
- The patients who have GI malignancies,the patients who are over ASA classification class III.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Aspirin holding group
Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy.
The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
|
|
Experimental: Aspirin continuing group
Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
|
Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
postpolypectomy bleeding rate
Time Frame: bleeding after polypectomy within 30 days
|
bleeding after polypectomy within 30 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Hemorrhage
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- KASIDPOLYP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding Complication During Colon Polypectomy
-
Indiana UniversityCompletedProcedural Bleeding | Delayed Bleeding | Post-Polypectomy Syndrome | Post Procedural ComplicationUnited States
-
VA Office of Research and DevelopmentCompletedPolypectomy | Post-polypectomy Bleeding | Elective ColonoscopyUnited States
-
Chinese University of Hong KongRecruitingPost Polypectomy BleedingHong Kong
-
Renmin Hospital of Wuhan UniversityNot yet recruitingColorectal Polyp | Post-polypectomy BleedingChina
-
Ningbo No. 1 HospitalCompletedBowel Preparation | Post-polypectomy Bleeding | Urgent ColonoscopyChina
-
Dallas VA Medical CenterCompletedColonoscopy | Post-polypectomy Bleeding | Anti-platelet TherapyUnited States
-
Incheon St.Mary's HospitalSeoul St. Mary's Hospital; Keimyung University Dongsan Medical Center; Soonchunhyang... and other collaboratorsCompletedPost Polypectomy BleedingKorea, Republic of
-
Showa Inan General HospitalCompletedPostpolypectomy Bleeding | Diminutive Colorectal Polyp | Cold Snare Polypectomy | Polypectomy Snare | Complete Resection RateJapan
-
Universitätsklinikum Hamburg-EppendorfFUJIFILM Deutschland, Branch office of FUJIFILM Europe GmbHRecruitingScreening Colonoscopy | Colonoscopic Control After Polypectomy | Suspected Colon PolypsGermany
-
Assiut UniversityCompletedBleeding During MyomectomyEgypt
Clinical Trials on Aspirin
-
The First Affiliated Hospital with Nanjing Medical...UnknownCoronary AtherosclerosisChina
-
Seoul National University HospitalCKD Pharmaceutical LimitedCompleted
-
Queen Mary University of LondonCancer Research UK; Barts and the London School of Medicine and DentistryCompletedProstate CancerUnited Kingdom
-
FANG HERecruitingPreeclampsia | Perinatal HaemorrhageChina
-
University of VigoRecruiting
-
Seoul National University HospitalCompletedCoronary Artery DiseaseKorea, Republic of
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPulmonary Disease, Chronic ObstructiveUnited States
-
Seoul National University HospitalCompletedHealthyKorea, Republic of
-
PLx PharmaCompletedDiabetes Mellitus, Type 2United States
-
BayerCompleted